Ophthalmic Research
Original Paper
Epiretinal Membrane of Proliferative Diabetic Retinopathy: An Immunohistochemical StudyHosoda Y.a · Okada M.a · Matsumura M.a · Ogino N.b · Honda Y.a · Nagai Y.caDepartment of Ophthalmology, Kyoto University, Faculty of Medicine, Kyoto; bDepartment of Ophthalmology, Aichi Medical University, Aichi; cDepartment of Tissue Physiology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: September 15, 1993
Accepted: February 23, 1993
Published online: December 11, 2009
Issue release date: 1993
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Abstract
Nineteen cases of epiretinal membrane (ERM) in proliferative diabetic retinopathy were studied using immunohistochemical methods. Antibodies against type I-IV collagen, fibronectin (FN), glial fibrillary acidic protein (GFAP), vimentin and the monoclonal antibody (MAB) against human Müller cells were used to examine the membranes. Type II collagen was found on one side of the ERMs in 95% of the cases. The other types of collagen, FN and vimentin were also identified in most cases. Müller cells (GFAP- and MAB-positive) were found in 2/19 cases (11 %), and astrocytes (GFAP-positive but MAB-negative) were found in 10/19 cases (53%). These results suggest that type II collagen (vitreal collagen) may act as a scaffolding in the formation of ERMs and that glial elements of the ERMs consist mainly of astrocytes.
© 1993 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: September 15, 1993
Accepted: February 23, 1993
Published online: December 11, 2009
Issue release date: 1993
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission